

Supplementary Fig. 1. Bar graphs showing the distribution of different mutational categories for each indicated algorithm. Numbers within the bars indicate the total count for each category.

Supplementary Figure 1



Supplementary Figure 2

Supplementary Fig. 2. A, Western blot showing protein levels in the indicated cancer cells ectopically expressing different mutant forms of IFNGR2, compared with wild-type (WT) and empty vector (EV) controls, following treatment with IFNγ (30 nM). **B,** Western blot showing protein levels in the indicated cancer cells ectopically expressing different variants of JAK2, compared with wild-type and empty vector (EV) controls, following treatment with IFNγ (30 nM). Panel on the right, heatmap showing changes in mRNA levels, based on quantitative RT-PCR (relative to *Actin*), of selected IFNγ target genes in the indicated cancer cell lines ectopically expressing the specified mutant proteins. **C,** Upper panel, representative clonogenic assays for the indicated cells infected with EV and WT or the indicated mutants and treated for 10 days with IFNγ at the indicated concentrations or untreated. Lower panel, viability of indicated cell lines and conditions, as in **B**. Lines, number of viable cells relative to the untreated cells. NR, not reached. IC_{50}, half maximal inhibitory concentration.